RxDoctor Payments Data

Chetna Jha, MD

Internal Medicine · Salem, VANPI 1316926009

Payments from drug & device makers

$1,177in general payments, 2019–2025

Across 79 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$462
  • Amgen$240
  • Astellas Pharma US Inc$169
  • Johnson & Johnson$131
  • Merck$39
  • Novartis$31
  • plus $104 from 7 others

What the payments were for

  • Food & beverage$1,17199%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,177 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$339,920
Medicare patients
634
Services billed
7,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$116,035
EliquisApixaban83$64,371
FarxigaDapagliflozin Propanediol93$61,688
JanuviaSitagliptin Phosphate67$50,924
XareltoRivaroxaban30$33,916
MounjaroTirzepatide32$33,266
ProliaDenosumab15$26,344
JardianceEmpagliflozin37$22,414
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$21,829
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,634
EntrestoSacubitril/Valsartan17$16,495
Tresiba Flextouch U-100Insulin Degludec19$15,708
Tresiba Flextouch U-200Insulin Degludec16$9,229
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$8,844
SynthroidLevothyroxine Sodium82$5,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$462$116,03596 claims
PfizerEliquis, Paxlovid$12$65,800121 claims
AstraZenecaFarxiga$23$61,68893 claims
MerckJanuvia$39$50,92467 claims
Johnson & JohnsonXarelto$131$33,91630 claims
AmgenProlia$240$26,34415 claims
Boehringer IngelheimJardiance$12$22,41437 claims
GSKTrelegy Ellipta$12$16,63425 claims
NovartisEntresto$31$16,49517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Salem

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →